Asean manufacturer hopes CanSino Covid-19 vaccine included in Malaysia s booster programme | Malaysia malaymail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from malaymail.com Daily Mail and Mail on Sunday newspapers.
SOLUTION Group Bhd has entered into an agreement with the Ministry of Health (MoH) to supply 3.5 million doses of Covid-19 vaccines produced in China to the government.
Solution Group to supply CanSino vaccine in Malaysia
A
-
Solution Group Bhd’s (SGB) wholly-owned subsidiary Solution Biologics Sdn Bhd (Solbio) has signed a finished product and a bulk product agreement today with CanSino Biologics Inc for the supply of the Recombinant Ad5-nCoV vaccine for use against Covid-19.
In a statement, the group said the finished product agreement allows Solbio to purchase and CanSino to supply the finish product vaccine for emergency use in Malaysia.
Copy URL
The finished product agreement allows Solution Biologics to purchase and CanSino to supply the finished vaccine for emergency use in Malaysia. – AFP pic, July 30, 2021.
SOLUTION Group Bhd’s (SGB) wholly owned subsidiary, Solution Biologics Sdn Bhd (Solbio) has signed a finished product and a bulk product agreement today with CanSino Biologics Inc for the supply of the Recombinant Ad5-nCoV vaccine against Covid-19.
In a statement, the group said the finished product agreement allows Solbio to purchase and CanSino to supply the finished vaccine for emergency use in Malaysia.
Effective July 2018, access to full reports will only be available with a subscription. Sign-up now and enjoy one (1) week free access!
FILE PHOTO: Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020. China Daily via REUTERS
KUALA LUMPUR (Bernama): Solution Group Bhd’s (SGB) wholly-owned subsidiary, Solution Biologics Sdn Bhd (SolBio) has signed a finished product and a bulk product agreement today with CanSino Biologics Inc for the supply of the Recombinant Ad5-nCoV vaccine for use against Covid-19.
In a statement, the group said the finished product agreement allows SolBio to purchase and CanSino to supply the finish product vaccine for emergency use in Malaysia.